Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Publication | Open Access

DOI Full Paper Access

582

Citations

References

2016

Year

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski, Maurilio Ponzoni, Martina Deckert, Letterio S. Politi, Valter Torri, Christopher P. Fox, Paul La Rosée, Elisabeth Schorb,

The Lancet Haematology

Abstract

References